Comparing two treatments for advanced breast cancer with low hormone receptor
Part of Cancer clinical trials.
This trial compares two treatment options for advanced breast cancer that has low hormone receptor levels and is HER2-negative. It tests whether a combination of chemotherapy followed by maintenance therapy works better than a CDK4/6 inhibitor combined with hormone therapy. This is for people who have not had chemotherapy for their advanced disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have advanced breast cancer confirmed by biopsy.
- Your cancer is hormone receptor low (1-50% ER positive by IHC, or ER under 1% with PR 1% or more, or other patterns your doctor can evaluate).
- Your cancer is HER2-negative (IHC 0 or 1+, or FISH negative if IHC 2+).
- You have at least one measurable tumor lesion.
- You have not had chemotherapy for advanced disease, but you may have had hormone therapy.
- You have not taken a CDK4/6 inhibitor before, or if you did, your cancer came back more than 1 year after stopping.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a sequence of three drugs: first trastuzumab rezetecan (a targeted therapy), then a CDK4/6 inhibitor plus hormone therapy. It's for people with a type of breast cancer called HR-positive, HER2-low or ultra-low that has spread or come back and has already progressed on a CDK4/6 inhibitor and hormone therapy.
This trial tests a combination of three drugs (chidamide, an angiogenesis inhibitor, and fulvestrant) for advanced hormone-positive, HER2-negative breast cancer that has worsened after CDK4/6 inhibitor treatment. The goal is to see if this combination can slow cancer growth for a longer time.
This trial tests two targeted drugs, trastuzumab rezetecan and trastuzumab deruxtecan, to see which works better for HER2-positive breast cancer that has spread or cannot be removed by surgery. These drugs target the HER2 protein on cancer cells to slow or stop their growth.
This study looks at how well CDK4/6 inhibitors combined with hormone therapy work in real-world settings for people with a certain type of advanced breast cancer (HR+/HER2-). It aims to understand the best treatment path and what happens next.
This trial tests whether adding a CDK4/6 inhibitor (a type of targeted pill) to standard hormone therapy after surgery can lower the risk of breast cancer coming back in women with high-risk, hormone-receptor-positive, HER2-positive early breast cancer.
This trial tests whether adding a targeted therapy (a CDK4/6 inhibitor) to standard hormone therapy can let some people safely skip chemotherapy. It is for early-stage, hormone-positive breast cancer that is also HER2-positive, and aims to reduce side effects while keeping the cancer from coming back.
Hear when a new Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.